Vertebral compression fractures: Manage aggressively to prevent sequelae

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 2, 2003, Pages 147-156

  Mazanec, Daniel J ^a   Mompoint, Alex ^a   Podichetty, Vinod K ^a   Potnis, Amarish ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIDEPRESSANT AGENT; CALCITONIN; CALCIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BACKACHE; BED REST; BRACE; CHRONIC PAIN; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG USE; HUMAN; KIDNEY FAILURE; MINIMALLY INVASIVE SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSIS; OSTEOPOROSIS; PHYSICAL DISABILITY; REVIEW; SAFETY; SPINE MALFORMATION; SPINE STABILIZATION; STOMACH DISEASE; SYMPTOMATOLOGY; VERTEBRA FRACTURE;

EID: 0037293555     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.2.147     Document Type: Review

References (83)

1. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7:221-227.
2. Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992; 13(suppl 2):S27-S31.
3. Holbrook TL, Grazier K, Kelsey JL, Stanffer RN. The frequency of occurrence, impact and cost of musculoskeletal condition in the United States. Chicago: American Academy of Orthopedic Surgeons, 1985.
4. Riggs L, Melton LJ. The worldwide problem of osteoporosis. Insights afforded by epidemiology. Bone 1995; 17(suppl 5):505S-511S.
5. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103:125-195.
6. Patel U, Skingle S, Campbell GA, Crisp AJ, Boyle IT. Clinical profile of acute vertebral compression fractures in osteoporosis. Br J Rheumatol 1991; 30:418-421.
7. Baba H, Maezawa Y, Kamitani K, et al. Osteoporotic vertebral collapse with late neurologic complications. Paraplegia 1995; 33:281-289.
8. Heggeness MH. Spine fracture with neurological deficit in osteoporosis. Osteoporosis Int 1993; 3:215-221.
9. Kaplan PA, Orton DF, Asleson RJ. Osteoporosis with vertebral compression fractures, retropulsed fragments, and neurologic compromise. Radiology 1987; 165:533-535.
10. Lee YL, Yip KM. The osteoporotic spine. Clin Orthop 1996; 323:91-97.
11. Nevitt M, Ettinger B, Black D, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128:793-800.
12. Lukert B. Vertebral compression fractures: How to manage pain, avoid disability. Geriatrics 1994; 49:22-26.
13. Gold DJ. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18:1855-1895.
14. Smith K, Bradley S, Kauffman C. Fever of unknown origin in the elderly: lymphoma presenting as vertebral compression fractures. J Am Geriatr Soc 1994; 42:88-92.
15. Naul GL, Peet GP, Maupin BW. Avascular necrosis of the vertebral body: MR imaging. Radiology 1989; 172:219-222.
16. Lecouvet F, Malghem J, Michaux L, et al. Vertebral compression fractures in multiple myeloma. Part II. Assessment of fracture risk with MR imaging of spinal bone marrow. Radiology 1997; 204:201-205.
17. Moulopoulos L, Yoshimitsu K, Johnston D, Leeds N, Libshitz H. MR prediction of benign and malignant vertebral compression fractures. J Mag Reson Imaging 1996; 6:667-674.
18. Lyles KW. Management of patients with vertebral compression fractures. Pharmacotherapy 1999; 19:21S-24S.
19. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:68-71.
20. Schlaich C, Minne HW, Bruckner T, et al. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998; 8:261-267.
21. Benzel EC. Biomechanics of Spine Stabilization, 1st ed. Illinois: AANS Publications, 2001:74-75.
22. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320-323.
23. Lyles K, Gold D, Shipp KM, Pieper CF, Martinez S, Mulhausen PL. Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 1993; 94: 595-601.
24. Licata A. Quality of life of osteoporotic patients: the impact of vertebral compression fractures. Advances in Osteoporotic Fracture Management 2001; 1:2-6.
25. Oleksik A, Lips P. Health related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Min Res 2000; 15:1384-1392.
26. Heany RP. The natural history of vertebral osteoporosis. Is low bone mass an epiphenomenon? Bone 1992; 13:523-526.
27. Kado D, Browner W, Palermo L, et al. Vertebral fractures and mortality in older women. A prospective study. Arch Intern Med 1999; 159:1215-1220.
28. Van Gelderen WF, al-Hindawi M, Gale RS, Steward AH, Archibald CG. Significance of short tau inversion recovery magnetic resonance sequence in the management of skeletal injuries. Australas Radiol 1997; 41:13-15.
29. Gates GF. SPECT bone scanning of the spine. Semin Nucl Med 1998; 28:78-94.
30. Maynard SA, Jensen ME, Schweickert PA, Marx WF, Short JG, Kallmes DF. Value of bone scan imaging in predicting pain relief from percutaneous vertebroplasty in osteoporotic vertebral fractures. Am J Neuroradiol 2000; 21:1807-1812.
31. Baur A, Stabler A, Bruning R, et al. Diffusion-weighted MR imaging of bone marrow differentiation of benign vs pathologic compression fractures. Radiology 1998; 207:349-356.
32. Rupp R, Ebraheim N, Coombs RJ. Magnetic resonance imaging differentiation of compression spine fractures or vertebral lesions caused by osteoporosis or tumor. Spine 1995; 20:2499-2504.
33. Lecouvet F, Vande Berg B, Maldague B, et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology 1997; 204:195-199.
34. Rapado A. General management of vertebral fractures. Bone 1996; 18:191S-196S.
35. Lyritis GP, Tsakalakos N, Magrases B, Karachaluo T, Yiatzides A, Tseksura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo controlled clinical study. Calcif Tiss Int 1991; 49:369-372.
36. Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11:205-209.
37. Lyritis GP, Ioannides GV, Karachalus T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic crush fractures: a prospective double-blind, randomized, clinical study. Clin J Pain 1999; 15:284-289.
38. Rifat SF, Kiningham RB, Pegg JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Prac 1992; 35:93-96.
39. Lyritis GP, Paspate I, Karachakor T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. Acta Orthopaedic Scandinava 1997; 275:112-114.
40. Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 1998; 44:2160-2166.
41. Kreeger L, Hutton-Potts J. The use of calcitonin in the treatment of metastatic bone pain. J Pain Symptom Manage 1999; 17:2-5.
42. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1992; 49:189-182.
43. Szanto J, Jozsef S, Rado J, Jahos E, Hindy I, Eckhardt S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1986; 43:69-72.
44. Azria M. Possible mechanism of the analgesic action of calcitonin. Bone 2002; 30(suppl 1):S80-S83.
45. Roth A, Kolark K. Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology 1966; 43:283-287.
46. Laurian L, Oberman Z, Graf E, Gilad S, Hoerer E, Simantov R. Calcitonin induced increased ACTH, β-endorphin and cortical secretion. Horm Metab Res 1981; 18:268-271.
47. Yoshimura M. Analgesic mechanisms of calcitonin. J Bone Min Metab 2000; 18:230-233.
48. Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone 2002; 30(suppl 1):71-74.
49. Azria M. The Calcitonins, Physiology and Pharmacology. Basel, Switzerland: Karger, 1989.
50. Chambers TJ, Dunn CJ. Pharmacological control of osteolytic mobility. Calcif Tiss Int 1983; 35:566-579.
51. Whelton A, Schulman G, Wallemork C, et al. Effect of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160:1465-1470.
52. Wolfe MM, Lichtenstein DR, Singh G. Medical progress: gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340:1888-1899.
53. Heerdink ER, Leufkens HG, Herings RN, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998; 158:1108-1112.
54. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: The Rotterdam Study. Arch Intern Med 2002; 162:265-270.
55. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160:777-784.
56. Bonner FJ, Chestnut CH, Fitzsimmons A, et al. Osteoporosis. In: Delisa JA, Gans BM, Bockenek WL, et al, editors. Rehabilitation Medicine: Principles and Practice, 3rd ed. Philadelphia: Lippincott-Raven, 1998:1453-1476.
57. Fisher SV, Winter RB. Spinal orthoses in rehabilitation. in: Braddom RL, editor. Physical Medicine and Rehabilitation. Philadelphia: W.B. Saunders Company, 1996:359-368.
58. Stillo JV, Stein AB, Ragnarson KT. Low back orthoses. Phys Med Rehab Clin North Am 1992; 3:57-94.
59. Sinaki M. Musculoskeletal rehabilitation. In: Riggs BL, Melton LJ, editors. Osteoporosis: Etiology, Diagnosis, and Management, 2nd ed. Philadelphia: Lippincott-Raven, 1995:435-473.
60. Galibert P. Note préliminaire sur le traitement des angiomes vertébraux par vertébroplastie acrylique. Neurochirurgie 1987; 33:166-167.
61. Garfin S, Yuan H, Reiley M. New technologies in spine. Kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine 2001; 14:1511-1515.
62. Lapras J, Motto LC. Injection percutanée de methylmétacrylate dans le traitement de l'ostéoporose et ostéolyse vertébrale grave. Ann Chir 1987; 43:371-375.
63. Mathis J, Barr JD, Belkoff S, et al. Percutaneous vertebroplasty: a developing standard of care for vertebral compression fractures. Am J Neuroradiol 2001; 22:373-381.
64. Jensen ME, Evans AJ, Mathis JM, et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. Am J Neuroradiol 1997; 18:1897-1904.
65. Cotten A, Bounty N, Cortet B, et al. Percutaneous vertebroplasty: state of the art. Radiographics 1998; 18:311-323.
66. Daramond H. Percutaneous vertebroplasty with polymethylmethacrylate: technique, indications, and results. Radiol Clin North Am 1998; 36:533-546.
67. Watts NB, Harris ST. Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporosis Int 2001; 12:429-437.
68. Ryu KS, Park CK, Kim MC, Kang JK. Dose-dependent epidural leakage of polymethylmethacrylate after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures. J Neurosurg 2002; 96(1 Suppl):56-61.
69. Lieberman IH, Dudeney S, Reinhardt M-K, Bell G. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 2001; 26:1631-1638.
70. Phillips FM, Paul R, Lierberman I. Kyphoplasty for the treatment of osteoporotic and osteolytic vertebral compression fractures. Adv Osteo Fract Manage 2001; 1:7-11.
71. Garfin S, Reilley M. Minimally invasive treatment of osteoporotic vertebral body compression fractures. Spine J 2002; 2:76-80.
72. Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23:16-37.
73. Milott JL, Green SS, Schapira MM. Osteoporosis: evaluation and treatment. Comp Ther 2000; 26:183-189.
74. Lane JM, Russel L, Khan SN. Osteoporosis. Clin Orthop 2000; 372:139-150.
75. Wade JP. Osteoporosis. Can Med Assoc J 2001; 165:45-50.
76. Highlights of the fourth Annual Conference on Osteoporosis, Amelia Island, Florida, February 22-24, 2001. South Med J 2001; 94:561-568.
77. Black DM, Thompson DE, Bauer DC, et al, for the FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85:4118-4124.
78. Sharpe M, Noble S, Spencer CM. Alendronate. an update of its use in osteoporosis. Drugs 2001; 61:999-1039.
79. Reginster J, Minne HW, Sorensen OH, et al, for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11:83-91.
80. Harris ST, Watts NB, Genant HK, et al, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282:1344-1352.
81. Ettinger B, Black DM, Mitlak BH, et al, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645.
82. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162:1140-1143.
83. Neer R, Arnaud C, Zanchetta JR, et al. Effects of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.